Expanding innovative portfolio may drive gains for Sun Pharma stock

Lerodalcibep licensing deal, growth in the US portfolio and tariff relief offer triggers, while the proposed Organon acquisition could broaden its global reach

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.business-standard.com)